Role of Aberrant Glycosylation of IgA1 Molecules in the Pathogenesis of IgA Nephropathy

Studies of the properties of immune complexes (IC) in the circulation, urine, and mesangium of IgA nephropathy (IgAN) patients have provided data relevant to the pathogenesis of this disease. IC contain predominantly polymeric IgA1 molecules which are deficient in galactose (Gal) residues on O-linked glycan chains in the hinge region (HR) of their heavy (H) chains. As a result of this aberrancy, a novel antigenic determinant(s) involving N-acetylgalactosamine (GalNAc) and perhaps sialic acid (SA) of O-linked glycans is generated and recognized by naturally occurring GalNAc-specific antibodies. Thus, IC in IgAN consist of Gal-deficient IgA1 molecules as an antigen, and GalNAc-specific IgG and/or IgA1 as an antibody. IgG antibodies to Gal-deficient IgA1 are probably induced by cross-reactive microbial antigens; they are present at variable levels not only in humans with or without IgAN but also in many phylogenetically diverse vertebrate species. Incubation of human mesangial cells with IC from sera of IgAN patients indicated that stimulation of cellular proliferative activity was restricted to the large (>800 kDa) complexes. These findings suggest that experimental approaches that prevent the formation of large Gal-deficient IgA1-IgG IC may be applied ultimately in an immunologically mediated therapy.

[1]  M. J. Chalmers,et al.  Analysis of O-glycan heterogeneity in IgA1 myeloma proteins by Fourier transform ion cyclotron resonance mass spectrometry: implications for IgA nephropathy , 2007, Analytical and bioanalytical chemistry.

[2]  B. Julian,et al.  Patients with IgA nephropathy have increased serum galactose-deficient IgA1 levels. , 2007, Kidney international.

[3]  B. Julian,et al.  Identification and characterization of CMP-NeuAc:GalNAc-IgA1 alpha2,6-sialyltransferase in IgA1-producing cells. , 2007, Journal of molecular biology.

[4]  B. Julian,et al.  IgA nephropathy: current views of immune complex formation. , 2007, Contributions to nephrology.

[5]  B. Julian,et al.  Reactivities of N-acetylgalactosamine-specific lectins with human IgA1 proteins. , 2007, Molecular immunology.

[6]  B. Julian,et al.  IgA-containing immune complexes in the urine of IgA nephropathy patients. , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[7]  R. Cummings,et al.  Protein glycosylation: Chaperone mutation in Tn syndrome , 2005, Nature.

[8]  J. Novak,et al.  Heterogeneity of IgG Glycosylation in Adult Periodontal Disease , 2005, Journal of dental research.

[9]  J. Woof,et al.  Mucosal immunoglobulins , 2005, Immunological reviews.

[10]  H. Cooper,et al.  Determination of Aberrant O-Glycosylation in the IgA1 Hinge Region by Electron Capture Dissociation Fourier Transform-Ion Cyclotron Resonance Mass Spectrometry* , 2005, Journal of Biological Chemistry.

[11]  J. Novak,et al.  Increased levels of galactose-deficient IgG in sera of HIV-1-infected individuals , 2005, AIDS.

[12]  B. Julian,et al.  IgA1-containing immune complexes in IgA nephropathy differentially affect proliferation of mesangial cells. , 2005, Kidney international.

[13]  R. Coppo,et al.  Aberrant glycosylation in IgA nephropathy (IgAN). , 2004, Kidney international.

[14]  J. Feehally,et al.  New insights into the pathogenesis of IgA nephropathy , 2003, Springer Seminars in Immunopathology.

[15]  H. Narimatsu,et al.  Initiation of O-Glycan Synthesis in IgA1 Hinge Region Is Determined by a Single Enzyme, UDP-N-Acetyl-α-d-galactosamine:PolypeptideN-Acetylgalactosaminyltransferase 2* , 2003, The Journal of Biological Chemistry.

[16]  H. Narimatsu,et al.  Molecular Cloning and Characterization of a Novel UDP-Gal:GalNAcα Peptide β1,3-Galactosyltransferase (C1Gal-T2), an Enzyme Synthesizing a Core 1 Structure of O-Glycan* , 2002, The Journal of Biological Chemistry.

[17]  R. Cummings,et al.  A unique molecular chaperone Cosmc required for activity of the mammalian core 1 β3-galactosyltransferase , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[18]  M. Lam,et al.  Size-dependent binding of IgA to HepG2, U937, and human mesangial cells. , 2002, The Journal of laboratory and clinical medicine.

[19]  B. Julian,et al.  Interactions of human mesangial cells with IgA and IgA-containing immune complexes. , 2002, Kidney international.

[20]  N. Saitou,et al.  Adaptive evolution of the IgA hinge region in primates. , 2002, Molecular biology and evolution.

[21]  B. Julian,et al.  Pathogenic potential of galactose‐deficient IgA1 in IgA nephropathy , 2002 .

[22]  R. Cummings,et al.  Cloning and Expression of Human Core 1 β1,3-Galactosyltransferase* , 2002, The Journal of Biological Chemistry.

[23]  B. Julian,et al.  Progress in Molecular and Genetic Studies of IgA Nephropathy , 2001, Journal of Clinical Immunology.

[24]  J. Barratt,et al.  Mesangial IgA1 in IgA nephropathy exhibits aberrant O-glycosylation: observations in three patients. , 2001, Kidney international.

[25]  Y. Hiki,et al.  Mass spectrometry proves under-O-glycosylation of glomerular IgA1 in IgA nephropathy. , 2001, Kidney international.

[26]  J. Marth,et al.  Genetic remodeling of protein glycosylation in vivo induces autoimmune disease. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[27]  J. Novak,et al.  Heterogeneity of O-glycosylation in the hinge region of human IgA1. , 2000, Molecular immunology.

[28]  K. Lai,et al.  Absence of CD89, polymeric immunoglobulin receptor, and asialoglycoprotein receptor on human mesangial cells. , 2000, Journal of the American Society of Nephrology : JASN.

[29]  B. Julian,et al.  Circulating immune complexes in IgA nephropathy consist of IgA1 with galactose-deficient hinge region and antiglycan antibodies. , 1999, The Journal of clinical investigation.

[30]  P. Delves,et al.  The effect on IgG glycosylation of altering beta1, 4-galactosyltransferase-1 activity in B cells. , 1998, Glycobiology.

[31]  R. Dwek,et al.  The Glycosylation and Structure of Human Serum IgA1, Fab, and Fc Regions and the Role of N-Glycosylation on Fcα Receptor Interactions* , 1998, The Journal of Biological Chemistry.

[32]  J. Mestecky,et al.  Structural heterogeneity of glycans in IgA molecules: Implications for IgA nephropathy , 1997 .

[33]  B. Julian,et al.  Galactose-deficient IgA1 in sera of IgA nephropathy patients is present in complexes with IgG. , 1997, Kidney international.

[34]  R. Dwek.  Glycobiology: more functions for oligosaccharides , 1995, Science.

[35]  R. Dwek,et al.  Glycosylation changes of IgG associated with rheumatooid arthritis can activate complement via the mannose-binding protein , 1995, Nature Medicine.

[36]  B. Julian,et al.  Defective galactosylation and clearance of IgA1 molecules as a possible etiopathogenic factor in IgA nephropathy. , 1993, Contributions to nephrology.

[37]  S. Rusconi,et al.  Persistent repression of a functional allele can be responsible for galactosyltransferase deficiency in Tn syndrome. , 1993, The Journal of clinical investigation.

[38]  A. Varki.  Biological roles of oligosaccharides: all of the theories are correct , 1993, Glycobiology.

[39]  B. Julian,et al.  Binding of serum immunoglobulins to collagens in IgA nephropathy and HIV infection. , 1992, Kidney international.

[40]  K. Komiyama,et al.  Site of Catabolism of Autologous and Heterologous IgA in Non‐Human Primates , 1990, Scandinavian journal of immunology.

[41]  L. Gesualdo,et al.  Defective oral tolerance promotes nephritogenesis in experimental IgA nephropathy induced by oral immunization. , 1990, Journal of immunology.

[42]  S. Jackson.  Immunoglobulin-antiimmunoglobulin interactions and immune complexes in IgA nephropathy. , 1988, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[43]  F. Ballardie,et al.  AUTOIMMUNITY IN IgA NEPHROPATHY , 1988, The Lancet.

[44]  J. Mestecky,et al.  Receptor-mediated binding and uptake of immunoglobulin A by human liver. , 1988, Gastroenterology.

[45]  B. Julian,et al.  Aberrant synthesis of antibodies directed at the Fab fragment of IgA in patients with IgA nephropathies. , 1987, Clinical immunology and immunopathology.

[46]  D. Delacroix,et al.  Intravascular and mucosal immunoglobulin A: two separate but related systems of immune defense? , 1987, Annals of internal medicine.

[47]  C. Czerkinsky,et al.  Normal human sera contain antibodies directed at Fab of IgA. , 1987, Journal of immunology.

[48]  J. Mestecky,et al.  The human IgA system: a reassessment. , 1986, Clinical immunology and immunopathology.

[49]  B. Julian,et al.  Circulating immune complexes and immunoglobulin A rheumatoid factor in patients with mesangial immunoglobulin A nephropathies. , 1986, The Journal of clinical investigation.

[50]  K. Lai,et al.  The immunochemical characterization of the light chains in the mesangial IgA deposits in IgA nephropathy. , 1986, American journal of clinical pathology.

[51]  H. Wigzell,et al.  Biological significance of carbohydrate chains on monoclonal antibodies. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[52]  M. Lamm,et al.  Experimental IgA nephropathy induced by oral immunization , 1983, The Journal of experimental medicine.

[53]  J. C. Collins,et al.  IgA interaction with the asialoglycoprotein receptor. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[54]  A. Michael,et al.  Selective deposition of immunoglobulin A1 in immunoglobulin A nephropathy, anaphylactoid purpura nephritis, and systemic lupus erythematosus. , 1980, The Journal of clinical investigation.

[55]  S. Roseman,et al.  Sialic acids. 13. A uridine diphosphate D-galactose: mucin galactosyltransferase from porcine submaxillary gland. , 1971, The Journal of biological chemistry.

[56]  J. Dausset,et al.  Acquired hemolytic anemia with polyagglutinability of red blood cells due to a new factor present in normal human serum (Anti-Tn). , 1959, Blood.

[57]  B. Julian,et al.  IgA nephropathy and Henoch-Schoenlein purpura nephritis: aberrant glycosylation of IgA1, formation of IgA1-containing immune complexes, and activation of mesangial cells. , 2007, Contributions to nephrology.

[58]  B. Julian,et al.  IgA nephropathy: a clinical overview. , 2007, Contributions to nephrology.

[59]  Yasuhiko Tomino,et al.  IgA nephropathy: characterization of IgG antibodies specific for galactose-deficient IgA1. , 2007, Contributions to nephrology.

[60]  M. Kilian,et al.  Chapter 15 – Microbial Evasion of IgA Functions , 2005 .

[61]  M. Kerr,et al.  Chapter 9 – Mucosal Immunoglobulins , 2005 .

[62]  B. Julian,et al.  IgA-associated renal diseases: Antibodies to environmental antigens in sera and deposition of immunoglobulins and antigens in glomeruli , 2004, Journal of Clinical Immunology.

[63]  岩崎 裕子.  Initiation of O-glycan synthesis in IgA1 hinge region is determined by a single enzyme, UDP-N-acetyl-α-D-galactosamine : Polypeptide N-acetylgalactosaminyltransferase 2 , 2003 .

[64]  T. Tanaka,et al.  [Tn syndrome]. , 1998, Ryoikibetsu shokogun shirizu.

[65]  O. Hashim,et al.  Alterations in the IgA carbohydrate chains influence the cellular distribution of IgA1. , 1995, Contributions to nephrology.

[66]  J. Davin.  Pathogenesis of IgA nephropathy. , 1995, Acta clinica Belgica.

[67]  D. Chevet,et al.  Impairment of jacalin binding to serum IgA in IgA nephropathy , 1990, Journal of clinical laboratory analysis.

[68]  Y. Nomoto,et al.  Pathogenesis of IgA nephropathy , 1990 .

[69]  J. M. Epps,et al.  The role of the liver in catabolism of mouse and human IgA. , 1989, Immunological investigations.

[70]  J. Mcghee,et al.  Comparative Studies of the Biological Properties of Human IgA Subclasses , 1989 .

[71]  B. Julian,et al.  Antibodies directed at Fab of IgA in the sera of normal individuals and IgA nephropathy patients. , 1987, Advances in experimental medicine and biology.

[72]  J. Mestecky,et al.  IgA subclasses. , 1986, Monographs in allergy.

[73]  P. Zucchelli,et al.  [IgA nephropathy]. , 1985, Medicina clinica.